86 related articles for article (PubMed ID: 31501379)
21. Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Maschan A; Novichkova G; Miakova N; Persiantseva M
Pediatr Blood Cancer; 2016 Dec; 63(12):2243-2245. PubMed ID: 27434016
[TBL] [Abstract][Full Text] [Related]
22. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
23. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
24. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
Takahashi N; Tauchi T; Kitamura K; Miyamura K; Saburi Y; Hatta Y; Miyata Y; Kobayashi S; Usuki K; Matsumura I; Minami Y; Usui N; Fukuda T; Takada S; Ishikawa M; Fujimaki K; Gomyo H; Sasaki O; Ohishi K; Miyake T; Imai K; Suzushima H; Mitsui H; Togitani K; Kiguchi T; Atsuta Y; Ohtake S; Ohnishi K; Kobayashi Y; Kiyoi H; Miyazaki Y; Naoe T;
Int J Hematol; 2018 Feb; 107(2):185-193. PubMed ID: 28929332
[TBL] [Abstract][Full Text] [Related]
25. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
26. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
29. Pyomyositis at the surgical site in a patient with chronic myeloid leukemia: a case report and literature review.
Takebayashi K; Sonoda H; Shimizu T; Ohta H; Minamiguchi H; Ishida M; Mekata E; Endo Y; Tani T; Tani M
World J Surg Oncol; 2016 Apr; 14():116. PubMed ID: 27094880
[TBL] [Abstract][Full Text] [Related]
30. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate.
Lakshmaiah KC; Bhise R; Purohit S; Abraham LJ; Lokanatha D; Suresh TM; Appaji L; Arunakumari BS; Govindbabu K
Leuk Lymphoma; 2012 Dec; 53(12):2430-3. PubMed ID: 22607062
[TBL] [Abstract][Full Text] [Related]
31. The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China.
Sheng G; Chen S; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
J Med Econ; 2017 Apr; 20(4):382-387. PubMed ID: 27937141
[TBL] [Abstract][Full Text] [Related]
32. Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Elm'hadi C; Khmamouche MR; Tanz R; Toreis M; Mahtat E; Allaoui M; Oukabli M; Messaoudi N; Errihani H; Ichou M
J Med Case Rep; 2017 Jan; 11(1):10. PubMed ID: 28069070
[TBL] [Abstract][Full Text] [Related]
33. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
35. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
36. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
[TBL] [Abstract][Full Text] [Related]
37. Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib.
Tsuzuki M; Inaguma Y; Handa K; Hasegawa A; Yamamoto Y; Watanabe M; Mizuta S; Maruyama F; Okamoto M; Emi N
Intern Med; 2009; 48(16):1433-5. PubMed ID: 19687593
[TBL] [Abstract][Full Text] [Related]
38. Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.
Vaidya S; Ghosh K; Shanmukhaiah C; Vundinti BR
Eur J Pharmacol; 2015 Oct; 765():124-30. PubMed ID: 26300393
[TBL] [Abstract][Full Text] [Related]
39. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J
Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients].
Jiang Q; Chen S; Jiang B; Jiang H; Lu Y; Huang X; Lu D
Beijing Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 35(2):136-40. PubMed ID: 12920827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]